O46.01 Antepartum hemorrhage with afibrinogenemia

Name of the Condition

• Antepartum Hemorrhage with Afibrinogenemia

Summary

Antepartum hemorrhage refers to bleeding from the genital tract during pregnancy, typically after 20 weeks of gestation. When associated with afibrinogenemia, the bleeding is exacerbated by a severe deficiency of fibrinogen, a critical protein for blood clotting. This condition can complicate management and increase risks to both the mother and fetus due to impaired clot formation.

Causes

Afibrinogenemia in antepartum hemorrhage may result from congenital deficiencies (e.g., inherited fibrinogen disorders) or acquired conditions such as severe liver disease, disseminated intravascular coagulation (DIC), or massive blood loss that depletes fibrinogen stores. Pregnancy-related complications like placental abruption or previa can also trigger or worsen this coagulation defect.

Risk Factors

• Congenital fibrinogen deficiency
• Severe liver dysfunction
• Previous history of bleeding disorders
• Placental abruption or previa
• Multiple pregnancies
• Use of anticoagulant medications

Symptoms

• Vaginal bleeding (ranging from spotting to heavy flow)
• Excessive bruising or prolonged bleeding from minor injuries
• Fatigue or weakness (due to blood loss)
• Signs of coagulation issues, such as petechiae or uncontrolled bleeding

Diagnosis

Diagnosis involves assessing the bleeding pattern and evaluating coagulation status through laboratory tests, including fibrinogen levels, prothrombin time (PT), and activated partial thromboplastin time (aPTT). Imaging (e.g., ultrasound) may be used to identify obstetric causes of bleeding, while genetic testing can confirm congenital fibrinogen disorders.

Treatment Options

Treatment focuses on controlling bleeding and replacing fibrinogen. Interventions may include fibrinogen concentrate, cryoprecipitate, or fresh frozen plasma to restore clotting function. Obstetric management, such as monitoring fetal well-being or preparing for delivery, is also critical. In severe cases, blood transfusions or surgical intervention may be necessary.

Prognosis and Follow-Up

Prognosis depends on the severity of bleeding, underlying causes, and timely intervention. Close monitoring of fibrinogen levels and coagulation status is essential. Follow-up care includes regular obstetric evaluations and ongoing assessment of coagulation function to prevent recurrence.

Complications

• Severe maternal hemorrhage
• Fetal distress or preterm delivery
• Disseminated intravascular coagulation (DIC)
• Maternal or fetal mortality in extreme cases

Lifestyle & Prevention

• Avoid activities with high injury risk during pregnancy.
• Manage underlying conditions (e.g., liver disease) with medical guidance.
• Inform healthcare providers of any bleeding history or genetic disorders.
• Attend all prenatal appointments for early detection of complications.

When to Seek Professional Help

Seek immediate medical attention for:

• Heavy or persistent vaginal bleeding.
• Signs of shock (e.g., dizziness, rapid heart rate, low blood pressure).
• Uncontrolled bleeding from minor injuries.
• Abdominal pain or cramping accompanied by bleeding.

Tips for Medical Coders

Document the presence of afibrinogenemia and its relationship to the antepartum hemorrhage. Include details on laboratory findings (e.g., fibrinogen levels) and obstetric management. Ensure the code O46.01 is used only when afibrinogenemia is explicitly documented as the coagulation defect associated with the hemorrhage.